Laffer Tengler Investments Inc. Has $15.07 Million Stake in AbbVie Inc. $ABBV

Laffer Tengler Investments Inc. raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 4.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,066 shares of the company’s stock after buying an additional 2,868 shares during the quarter. AbbVie comprises 2.4% of Laffer Tengler Investments Inc.’s portfolio, making the stock its 9th biggest holding. Laffer Tengler Investments Inc.’s holdings in AbbVie were worth $15,066,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Brighton Jones LLC boosted its holdings in AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after acquiring an additional 3,401 shares during the period. Revolve Wealth Partners LLC increased its stake in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares during the period. Schnieders Capital Management LLC. lifted its position in shares of AbbVie by 5.0% during the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after purchasing an additional 789 shares during the last quarter. iA Global Asset Management Inc. boosted its stake in shares of AbbVie by 18.6% during the second quarter. iA Global Asset Management Inc. now owns 5,125 shares of the company’s stock valued at $951,000 after purchasing an additional 805 shares during the period. Finally, Fullcircle Wealth LLC grew its holdings in shares of AbbVie by 2.5% in the second quarter. Fullcircle Wealth LLC now owns 6,683 shares of the company’s stock worth $1,318,000 after purchasing an additional 165 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on ABBV. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research report on Tuesday, November 4th. Evercore lowered their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a report on Wednesday, February 4th. Scotiabank assumed coverage on AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective on the stock. HSBC raised AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Finally, Barclays assumed coverage on AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive topline Phase 3 AFFIRM results for risankizumab (SKYRIZI) subcutaneous induction in moderately to severely active Crohn’s disease, showing superiority vs. placebo and no new safety signals — a material clinical win that expands AbbVie’s immunology franchise and supports future uptake. AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn’s Disease
• Positive Sentiment: FDA approval for an oral combination of VENCLEXTA and acalabrutinib in previously untreated CLL adds an approved hematology-oncology option to AbbVie’s portfolio, supporting long-term revenue diversification in oncology. AbbVie’s New Data And Approval Test Growth And Valuation Story
• Positive Sentiment: Planned $380M investment to build two new active pharmaceutical ingredient manufacturing facilities in Illinois signals capacity expansion, vertical integration and potential margin/production benefits over time. Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now?
• Positive Sentiment: Multiple analyst/outlet pieces highlight AbbVie’s attractive dividend yield and steady payout growth, which can support investor demand from income-oriented funds and long-term investors. Why AbbVie Stock May Be the Ultimate Option for Dividend Investors
• Neutral Sentiment: Management will present at the Leerink Partners Global Healthcare Conference (fireside chat on March 10), providing another opportunity for guidance clarity and incremental investor Q&A but not an immediate catalyst. AbbVie to Present at the Leerink Partners Global Healthcare Conference
• Neutral Sentiment: Mentions in industry reports on continuous manufacturing and market trends underscore structural tailwinds for pharma manufacturing efficiency but are longer‑term and indirect for AbbVie’s near-term stock moves. Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players – AbbVie…
• Negative Sentiment: Despite the positive headlines, the stock is down today — likely reflecting short‑term profit-taking and a stretched valuation/PE that makes the name sensitive to market rotation and earnings expectations in the near term.

AbbVie Stock Down 0.4%

ABBV opened at $233.44 on Wednesday. The company has a market cap of $412.76 billion, a P/E ratio of 98.92, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34. The firm’s 50-day moving average price is $224.56 and its 200-day moving average price is $223.66. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same quarter last year, the business posted $2.16 EPS. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is 293.22%.

Insider Activity

In related news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.08% of the stock is currently owned by corporate insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.